Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $32.00 per share, for gross proceeds of $176 million before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by Aimmune. All of the shares to be sold in the offering will be offered by Aimmune. In addition, Aimmune has granted the underwriters of the offering a 30-day option to purchase up to an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Aimmune.

Aimmune currently expects to use the net proceeds from this offering to fund its ongoing clinical development of AR101, an investigational biologic for the treatment of patients with peanut allergy; regulatory activities related to the potential filing of a Biologics License Application and a Marketing Authorization Application for AR101; preparation for potential commercialization of AR101; research and development of additional CODIT™ product candidates; and for general corporate purposes.

The offering is expected to close on or about February 26, 2018, subject to satisfaction of customary closing conditions.

BofA Merrill Lynch, Cantor Fitzgerald & Co. and Piper Jaffray & Co. are acting as joint bookrunning managers for the offering. Credit Suisse and RBC Capital Markets are also acting as bookrunning managers. Roth Capital Partners and Wedbush PacGrow are acting as co-managers for the offering.

A registration statement relating to the securities being sold in this offering was filed with the Securities and Exchange Commission on December 28, 2017, and was automatically declared effective upon filing. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from: BofA Merrill Lynch, NC1-004-03, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, email: [e-mail]; or from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022; email: [e-mail]; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or email at [e-mail].